Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Replagal (agalsidase alfa)
BIOLOGICAL
2 trials
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
, Shire
Conditions
Fabry Disease
Phase 2
Safety Study of Replagal® Therapy in Children With Fabry Disease
Completed
NCT01363492
Shire
Fabry Disease
Start: 2011-05-12
End: 2013-04-17
Updated: 2021-06-09
Phase 4
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
Completed
NCT00097890
National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
Start: 2004-11-30
End: 2005-12-31
Target: 25
Updated: 2008-03-04
Related Papers
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
Drug Design Development and Therapy
2016-05-01
22 citations
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
2015-07-08
20 citations